Liver X receptors activation, through TO901317 binding, reduces neuroinflammation in Parkinson’s disease

The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson’s Disease Model

(2015) Rosalba Siracusa et al.   CNS & Neurological Disorders-Drug Targets

A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury

(2013) Irene Paterniti et al.   Journal of Neuroinflammation

LXR Agonists: New Potential Therapeutic Drug for Neurodegenerative Diseases

(2013) Pei Xu et al.   MOLECULAR NEUROBIOLOGY

Levodopa Activates Apoptosis Signaling Kinase 1 (ASK1) and Promotes Apoptosis in a Neuronal Model: Implications for the Treatment of Parkinson's Disease

(2011) Elizabeth A. Sabens Liedhegner et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Melatonin as a Neuroprotective Agent in the Rodent Models of Parkinson’s Disease: Is it All Set to Irrefutable Clinical Translation?

(2011) Naveen Kumar Singhal et al.   MOLECULAR NEUROBIOLOGY

Liver X receptor agonist treatment regulates inflammatory response after spinal cord trauma

(2009) Irene Paterniti et al.   JOURNAL OF NEUROCHEMISTRY

Neuroinflammation in Parkinson's disease: a target for neuroprotection?

(2009) Etienne C Hirsch et al.   LANCET NEUROLOGY

Behavioral Disinhibition and Reduced Anxiety-like Behaviors in Monoamine Oxidase B-Deficient Mice

(2009) Marco Bortolato et al.   NEUROPSYCHOPHARMACOLOGY

Cellular and Biochemical Actions of Melatonin which Protect Against Free Radicals: Role in Neurodegenerative Disorders

(2008) Genaro Ortiz et al.   Current Neuropharmacology

Glial reactions in Parkinson's disease

(2007) Patrick L. McGeer et al.   MOVEMENT DISORDERS